10q10k10q10k.net
Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.STOKEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

Top Holders

Holder% OwnedSharesChangeAs of
BlackRock, Inc.10.40%
5.4M
—2024-07-08
Lynx1 Capital Management LP9.90%
5.2M
▲ +3.30pp2024-11-14
Blue Horizon Enterprise Ltd.9.40%
5.0M
▼ -5.50pp2024-09-23
RTW Investments, LP9.30%
4.1M
—2024-02-14
Redmile Group, LLC9.00%
4.7M
▲ +3.10pp2024-11-14
Baker Bros. Advisors LP8.30%
4.4M
—2024-11-14
Cowen Financial Products LLC8.30%
3.7M
▲ +2.53pp2024-02-26
The Vanguard Group5.24%
2.8M
flat2024-11-12
FMR LLC0.01%
5.0K
—2024-02-09

Insider Transactions

Net 90d: −$3.19M · buys $0 / sells $3.19M
Range:
Action:
Role:
InsiderRoleAction
2026-04-01Barry TichoCHIEF MEDICAL OFFICERSell (open market)
1.8K
$32.66$60.0K
2026-03-20Jonathan AllanGENERAL COUNSEL & CORP SECSell (open market)
8.7K
$33.64$292.4K
2026-03-20Jonathan AllanGENERAL COUNSEL & CORP SECSell (open market)
601
$34.41$20.7K
2026-03-19Barry TichoCHIEF MEDICAL OFFICEROption exercise
1.4K
$2.19$3.0K
2026-03-19Barry TichoCHIEF MEDICAL OFFICERSell (open market)
1.5K
$29.99$43.8K
2026-03-18Jason HoittChief Patient OfficerSell (open market)
1.8K
$31.28$55.1K
2026-03-18Jason HoittChief Patient OfficerSell (open market)
139
$31.79$4.4K
2026-03-18Jason HoittChief Patient OfficerSell (open market)
30
$32.85$986
2026-03-18Barry TichoCHIEF MEDICAL OFFICERSell (open market)
6.1K
$31.28$190.8K
2026-03-18Barry TichoCHIEF MEDICAL OFFICERSell (open market)
483
$31.79$15.4K
1–10 of 40
Page 1 / 4